Stem Cell Therapy

Hemostemix (HMTXF) closed the first tranche of a private placement, raising $461,230 by issuing 4,193,000 Units at $0.11 each. Each Unit includes a share and a warrant exercisable at $0.15. Proceeds fund working capital and VesCell marketing. Finder’s fees were paid, and certain directors participated, triggering related party considerations with MI 61-101 exemptions. The closing is subject to regulatory approval, and securities are subject to a four-month hold period. The offering introduces potential dilution from new shares and warrants.

Adia Nutrition (OTCQB: ADIA) launches its second national TV campaign, promoting Adia Med’s stem cell therapies for sports injuries, orthopedic issues, chronic pain, and wound repair at its Winter Park, Florida clinic. Targeting the $25 billion wound care market, Adia Med aims to make regenerative treatments more accessible domestically. The company is in-network with UnitedHealthcare and Aetna, awaiting TRICARE approval. Florida’s SB1768, recognizing stem cell therapy’s benefits, boosts this initiative. The therapies provide alternatives to overseas medical tourism.

Hemostemix (HMTXF) has contracted Empire Market Ventures (EMV) to boost its market awareness. EMV, a New York-based consulting firm specializing in investor relations and strategic communications, will develop and implement investor engagement strategies using digital media and market intelligence. EMV will operate independently to provide unbiased counsel and ensure regulatory compliance. The goal of the partnership is to increase Hemostemix’s visibility and growth within the capital markets. The announcement was made on August 12, 2025.